Cargando…

Paclitaxel–ifosfamide–carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours

BACKGROUND: Malignant mixed Mullerian tumours (MMMTs) of the uterus and adnexa represent aggressive gynaecologic malignancies with a high rate of loco-regional and distant failure. For that reason, we evaluated the paclitaxel–ifosfamide–carboplatin (TICb) combination in patients with advanced MMMTs....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosmas, C, Vorgias, G, Tsakonas, G, Politis, P, Daladimos, T, Panagiotidi, E, Papachrysanthou, T, Moschovis, D, Kalinoglou, N, Tsavaris, N, Karabelis, A, Mylonakis, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185936/ https://www.ncbi.nlm.nih.gov/pubmed/21847127 http://dx.doi.org/10.1038/bjc.2011.316

Ejemplares similares

Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer
por: Kosmas, C, et al.
Publicado: (2009)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
por: Sokolova, Alexandra, et al.
Publicado: (2017)

Malignant peripheral nerve sheath tumor in neurobifromatosis type-1: two case reports
por: Kosmas, Christos, et al.
Publicado: (2009)

Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer
por: Kosmas, C, et al.
Publicado: (2003)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy
por: Tay, Tricia, et al.
Publicado: (2022)

Outcomes of Window Therapy with Carboplatin and Ifosfamide for Pediatric Osteosarcoma: A Case Series
por: Aiba, Hisaki, et al.
Publicado: (2023)

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
por: Mahdy, Ahmed, et al.
Publicado: (2023)

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
por: Thatcher, N., et al.
Publicado: (1989)

Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
por: Arakawa, Yoshiki, et al.
Publicado: (2013)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
por: Akce, Mehmet, et al.
Publicado: (2016)

Recurrent female adnexal tumor of probable Wolffian origin treated with debulking surgery, imatinib and paclitaxel/carboplatin combination chemotherapy: A case report
por: Wakayama, Akihiko, et al.
Publicado: (2017)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
por: Tsakonas, Georgios, et al.
Publicado: (2020)

Impact of dexamethasone, etoposide, ifosfamide and carboplatin as concurrent chemoradiotherapy agents for nasal natural killer/T-cell lymphoma
por: HATAYAMA, YOSHIOMI, et al.
Publicado: (2013)

Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
por: NAKAGAKI, Yuki, et al.
Publicado: (2022)

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
por: Perren, T. J., et al.
Publicado: (1993)

Leiomyoma development in Mayer-Rokitansky-Küster-Hauser syndrome: a case report and a narrative review of the literature
por: Blontzos, Nikolaos, et al.
Publicado: (2019)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
por: Elsayed, Ahmed Gamal, et al.
Publicado: (2017)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor
por: Kurobe, Masahiro, et al.
Publicado: (2014)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
por: Zhou, Ping, et al.
Publicado: (2015)

Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study
por: Mi, Mi, et al.
Publicado: (2020)

An Unconventional Regimen of Carboplatin and Paclitaxel in Metastatic Colorectal Carcinosarcoma: A Case Report and Review of Literature
por: Park, Changsu Lawrence, et al.
Publicado: (2023)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis
por: Fruscio, R, et al.
Publicado: (2008)

Partial Fanconi Syndrome Induced by Ifosfamide
por: Das, Sulagna, et al.
Publicado: (2019)

Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma
por: Scandurra, Giuseppa, et al.
Publicado: (2015)

Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer
por: von Amsberg, Gunhild, et al.
Publicado: (2022)

Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
por: Klaassen, U., et al.
Publicado: (1996)

Evaluation of Paclitaxel, Ifosfamide, and Cisplatin (TIP) Regimen on Penile Cancer in Adam Malik Medan: A Single Center 2 Years of Experience
por: Sitompul, Ardiansyah Periadi, et al.
Publicado: (2019)

Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer
por: Lee, C K, et al.
Publicado: (2011)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma
por: Devi, Kanta, et al.
Publicado: (2023)

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel
por: Jilaveanu, Lucia B., et al.
Publicado: (2013)

CARBOPLATIN-PACLITAXEL INDUCED ACUTE MULTI-VESSEL CORONARY THROMBOSIS
por: Fanous, Hanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aph32oof1b80ag0sf5v464bl9u